AMADOR BIOSCIENCE ANNOUNCES THE COMPLETION OF $60 MILLION SERIES B+ ROUND FINANCING
Amador Bioscience, a global translational sciences and clinical pharmacology CRO, announced today that it has completed 60MM USD Series B+ financing led by MSA Capital, a global private equity firm. Other participating investors include Series B Co-leads GL Ventures (venture capital arm of Hillhouse Group) and Sequoia Capital, and Series A lead VC Co-win Ventures.
“Amador’s vision is to be a leading global partner for biotherapeutics R&D success,” said Dr. Bing Wang, Amador CEO and Chairman of the Board. “We strive to provide global-standard translational sciences and clinical pharmacology services to biopharmaceutical companies in the US, China and EU. Completion of the back-to-back Series B and B+ financing marks a key milestone mirroring the End-of-Phase 2 (EOP2) in drug development. With this achievement, we’re committed to expanding our team and business, while keeping Amador’s pledge to provide efficient and high-quality work. We are blessed with the trust and support of our biopharmaceutical clients, employees, collaborators, and in particular our distinguished institutional investors. Together we continue building an innovative and efficient engine to accelerate the global R&D of novel drugs.”